Cardlytics (NASDAQ:CDLX) Stock Rating Lowered by William Blair


Share on StockTwits

Cardlytics (NASDAQ:CDLX) was downgraded by research analysts at William Blair from an “outperform” rating to a “market perform” rating in a report issued on Thursday, AR Network reports. The analysts noted that the move was a valuation call.

CDLX has been the topic of several other research reports. JPMorgan Chase & Co. increased their target price on shares of Cardlytics from $82.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, December 16th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Cardlytics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 22nd. Truist upped their target price on Cardlytics from $70.00 to $90.00 in a research note on Tuesday, November 3rd. Craig Hallum upped their price objective on Cardlytics from $70.00 to $82.00 and gave the company a “hold” rating in a research report on Tuesday, November 3rd. Finally, ValuEngine downgraded shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 1st. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $79.43.

Shares of NASDAQ:CDLX opened at $132.48 on Thursday. The firm has a market cap of $3.64 billion, a price-to-earnings ratio of -78.86 and a beta of 2.63. The firm has a fifty day moving average price of $134.77 and a 200 day moving average price of $92.68. Cardlytics has a fifty-two week low of $27.33 and a fifty-two week high of $150.46. The company has a debt-to-equity ratio of 1.14, a quick ratio of 6.08 and a current ratio of 6.08.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Saturday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.12. Cardlytics had a negative return on equity of 31.98% and a negative net margin of 23.91%. The business had revenue of $46.10 million during the quarter, compared to analyst estimates of $38.85 million. During the same period last year, the company earned $0.03 EPS. The company’s revenue for the quarter was down 18.3% on a year-over-year basis. As a group, research analysts predict that Cardlytics will post -2.08 earnings per share for the current year.

In other news, CEO Lynne Marie Laube sold 6,548 shares of the firm’s stock in a transaction on Friday, November 27th. The stock was sold at an average price of $119.27, for a total value of $780,979.96. Following the completion of the sale, the chief executive officer now owns 313,396 shares of the company’s stock, valued at approximately $37,378,740.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Scott D. Grimes sold 2,000 shares of the business’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of $81.05, for a total value of $162,100.00. Following the transaction, the chairman now owns 235,790 shares in the company, valued at $19,110,779.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 129,780 shares of company stock worth $15,063,051. 6.50% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of CDLX. Equitec Specialists LLC purchased a new position in Cardlytics during the third quarter valued at approximately $35,000. Captrust Financial Advisors purchased a new position in shares of Cardlytics during the 2nd quarter valued at approximately $54,000. Nisa Investment Advisors LLC increased its holdings in shares of Cardlytics by 241.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 990 shares of the company’s stock valued at $70,000 after purchasing an additional 700 shares in the last quarter. Advisor Group Holdings Inc. boosted its holdings in Cardlytics by 297.9% during the second quarter. Advisor Group Holdings Inc. now owns 2,053 shares of the company’s stock worth $142,000 after buying an additional 1,537 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Cardlytics during the third quarter valued at $184,000. 97.03% of the stock is currently owned by hedge funds and other institutional investors.

About Cardlytics

Cardlytics, Inc operates an advertising platform within financial institutions digital channels, which include online, mobile, email, and various real-time notifications in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Story: Special Purpose Acquisition Company (SPAC)

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.